

## 4DMedical completes A\$20m Placement to accelerate commercialisation & launches SPP

08 May 2023

### Highlights

- 4DMedical receives commitments for approximately \$20m via a Placement at A\$0.91 per share
- Demand for the Placement was multiple times more than \$20m, with participation by new and existing institutional and sophisticated investors, both domestically and offshore
- Proceeds from the Placement will accelerate commercialisation of 4DMedical's four-dimensional respiratory imaging platform
- The Company will also offer a Share Purchase Plan (SPP) of approximately A\$15m
- The SPP will provide all eligible shareholders the opportunity to participate in the transaction

**Melbourne, Australia, 08 May 2023:** Respiratory imaging technology company, 4DMedical Limited (ASX:4DX, "4DMedical" or the "Company") is pleased to announce it has completed a share placement (**Placement**) to institutional and sophisticated investors. The Placement will raise approximately A\$20m in gross proceeds.

The Placement will result in the issue of approximately 22 million shares at A\$0.91 per share (**Placement Shares**), within the Company's existing placement capacity under ASX Listing Rules 7.1. and 7.1A. The issue price represents a 19.8% discount to the last closing price on 3 May 2023, being the last day the Company traded prior to the Placement.

The Company will also offer eligible shareholders in Australia and New Zealand the opportunity to participate in a Share Purchase Plan (**SPP**). Eligible shareholders will be entitled to apply for up to A\$30,000 of new shares, targeting an additional A\$15m in gross proceeds. The Company reserves the right to accept oversubscriptions under the SPP, subject to the ASX Listing Rules and the *Corporations Act 2001*.

The SPP will be offered at the lower of:

- A\$0.91 per share; and
- a 2.5% discount to the VWAP of shares traded on the ASX during the five trading days up to the closing date of the SPP, rounded to the nearest half cent.

New shares issued under the Placement and SPP will have one unlisted free attaching option (**Option**) for every two new shares issued, with an exercise price of A\$1.365 and an expiry date of 31 December 2024. The Options will be issued subject to shareholder approval for the purpose of ASX Listing Rule 7.1.

Further details in relation to the SPP, including the scale-back policy, will be provided to eligible shareholders in a prospectus. Proceeds raised under the Placement and SPP will be used primarily to accelerate commercialisation of 4DMedical's respiratory imaging platform and significantly strengthen the Company's balance sheet.

#### Melbourne

Level 7 Melbourne Connect  
700 Swanston Street  
Carlton VIC 3053  
Tel: +61 (3) 9545 5940

#### Los Angeles

21255 Burbank Boulevard  
Suite 102  
Woodland Hills CA 91367  
Tel: +1 (818) 403-8490

4DMedical Limited  
ABN: 31 161 684 831  
Email: [info@4DMedical.com](mailto:info@4DMedical.com)  
[www.4DMedical.com](http://www.4DMedical.com)



#### 4DMedical Founder and CEO Andreas Fouras said:

*We are seeing real momentum in the commercialisation of our business. Our first hospital-based SaaS contract with the University of Miami establishes a framework for further contracts with US hospitals. The first commercial scan with Veterans Affairs demonstrates the immediacy of the very substantial opportunity with the VA. And most recently, the initiation of a pilot within the US Department of Defense presents a further exciting pipeline of growth.*

*The funds raised from the Placement and SPP will enable us to accelerate our commercialisation efforts and capitalise on our recent momentum. It will also provide us with balance sheet flexibility for future growth opportunities as our revenue profile continues to grow.*

*The SPP is particularly important to us to ensure our loyal shareholders are given the opportunity to participate in this capital raising. We are incredibly grateful to our shareholders for their continued support, and the 4D team is working tirelessly to deliver on our strategy to repay that faith.*

#### Key Dates for Capital Raising

Bell Potter Securities Limited is sole Lead Manager and bookrunner to the Placement and SPP.

Event	Timing (Sydney time)
Record Date for the SPP	7.00pm Friday, 5 May 2023
Lodgement of Prospectus for Placement and SPP	Wednesday, 10 May 2023
SPP opens	Wednesday, 10 May 2023
Lodgement of NOM for EGM to approve Options	Friday, 12 May 2023
Settlement of the Placement	Monday, 15 May 2023
Allotment of New Shares under the Placement	Tuesday, 16 May 2023
SPP closes	Wednesday, 24 May 2023
Announcement of results of the SPP	Monday, 29 May 2023
Allotment of New Shares under the SPP	Before 12.00pm Wednesday, 31 May 2023
EGM to approve issue of Options under Placement and SPP	Wednesday, 14 June 2023
Issue of Options under Placement and SPP (subject to EGM approval)	Thursday, 15 June 2023

*This timetable is indicative only and subject to change. The Company reserves the right to amend the dates at its discretion and without notice, subject to the ASX Listing Rules and the Corporations Act 2001 (Cth).*



–ENDS–

Authorised by the 4DMedical Board of Directors.

## Contacts

### Corporate

CFO

Simon Glover

[sglover@4dmedical.com](mailto:sglover@4dmedical.com)

### Administration

Company Secretary

Naomi Lawrie

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

### Media Enquiries

TCN

Julia Maguire

[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

## About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com).

For personal use only